We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interleukin-2 Suggested as Basis for Celiac Disease Diagnostic Test

By LabMedica International staff writers
Posted on 19 Aug 2019
A study designed to link changes in cytokine release following ingestion of gluten by individuals suffering from celiac disease found that interleukin-2 (IL-2) was the earliest and most prominent cytokine.

Investigators at the biotechnology company ImmusanT (Cambridge, MA, USA), the Walter and Eliza Hall Institute (Melbourne, Australia), and collaborators in the United States and Norway were searching for biomarkers that could be used in a simple blood test for diagnosis of celiac disease.

Currently, diagnosis of celiac disease is typically made by a combination of blood antibody tests and intestinal biopsies, augmented by specific genetic testing. More...
This approach is complicated by the fact that frequently the autoantibodies in the blood are negative, and many individuals have only minor intestinal changes with normal villi. Some celiac sufferers may have severe symptoms and be investigated for years before a diagnosis is achieved. Increasingly, diagnosis of celiac disease is being made in asymptomatic individuals, as a result of screening. Evidence regarding the effects of screening, however, has not been sufficient to determine its usefulness.

For the current study, the investigators injected celiac patients with gluten peptides, which induced gastrointestinal symptoms, particularly nausea and vomiting. In the second phase of the study, the patients consumed a diet including gluten.

Results revealed that peptide injection elevated at least 15 plasma cytokines, with IL-2, IL-8, and IL-10 being most prominent (fold-change increase at four hours of 272, 11, and 1.2, respectively). IL-2 and IL-8 were the only cytokines elevated at two hours, preceding onset of symptoms. After gluten ingestion, IL-2 was the earliest and most prominent cytokine (15-fold change at four hours).

Senior author Dr. Robert P. Anderson, chief scientific officer of ImmusanT, said, "For the first time we have described the inflammatory reaction that patients with celiac disease experience in the immediate hours after they are exposed to gluten. The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T-cells of the immune system. This response is similar to what happens when an infection is present, however for people with celiac disease, gluten is the trigger. This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without celiac disease who may be better served by other treatments for their chronic symptoms."

Contributing author Dr. Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute, said, "For the many people following a gluten-free diet without a formal diagnosis of celiac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten. This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine."

The study was published in the August 7, 2019, online edition of the journal Science Advances.

Related Links:
ImmusanT
Walter and Eliza Hall Institute


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.